<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: We previously established a novel method of primary culture for human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>This method, termed the CTOS method, involves the preparation of multicellular spheroids of primary <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells that are cultured so that cell-cell contact is maintained </plain></SENT>
<SENT sid="2" pm="."><plain>Here we applied the CTOS method to human urothelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>MATERIALS AND METHODS: CTOSs were prepared from xenografts or primary human bladder urothelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> following the same protocol used for human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>The CTOSs were characterized using immunohistochemistry, Western blot and PCR </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: We established a xenograft from a primary bladder urothelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> and isolated and cultured CTOSs from the xenograft <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>The CTOSs retained the characteristics of the original <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> as well as those of the xenograft </plain></SENT>
<SENT sid="7" pm="."><plain>HRG promoted the growth of the CTOSs </plain></SENT>
<SENT sid="8" pm="."><plain>Both inhibitors of PI3K and mTOR inhibited HRG-induced CTOS growth </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="49603">Lapatinib</z:chebi>, but not <z:chebi fb="0" ids="114785">erlotinib</z:chebi>, inhibited HRG-induced CTOS growth </plain></SENT>
<SENT sid="10" pm="."><plain>We also prepared CTOSs from <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> of bladder urothelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>The success rate of establishing primary CTOSs from non-muscle-invasive urothelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> was 90.7% and that from muscle-<z:e sem="disease" ids="C0677898" disease_type="Neoplastic Process" abbrv="">invasive cancer</z:e> was 68.2% </plain></SENT>
<SENT sid="12" pm="."><plain>The overall success rate was 84.2% </plain></SENT>
<SENT sid="13" pm="."><plain>HRG promoted the growth of primary CTOSs from 4 of 7 patients </plain></SENT>
<SENT sid="14" pm="."><plain>CONCLUSIONS: Here we report a method for establishing primary cultures of human urothelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="15" pm="."><plain>Stimulation of the growth by HRG in CTOSs from xenografts and <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> suggests the possibility of molecular targeting therapy against HER3 signaling for human urothelial <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="16" pm="."><plain>The CTOS method might be useful for selecting patients for molecular targeting drugs like <z:chebi fb="0" ids="49603">lapatinib</z:chebi> </plain></SENT>
</text></document>